N-acetylcysteine prevents glutathione decrease and does not interfere with paracetamol antinociceptive effect at...

Area of Science:

• Pharmacology
• Hepatology
• Pain Management

Background:

• Paracetamol (APAP) can cause liver damage even at recommended doses.
• Glutathione (GSH) is vital for detoxifying harmful APAP metabolites.
• N-Acetylcysteine (NAC) is an APAP antidote and a common mucoactive agent often co-administered with APAP.

Purpose of the Study:

• To investigate if NAC affects the pain-relieving efficacy of APAP.
• To determine if NAC can prevent GSH depletion when APAP is given at therapeutic doses.

Main Methods:

• A double-blind, randomized controlled study involving 24 healthy volunteers.
• Participants received APAP (1g four times daily) with either NAC or placebo for 4 days.
• Pain intensity, whole blood GSH levels, and liver enzymes were measured before and after treatment.

Main Results:

• APAP demonstrated similar pain-relieving effects in both the NAC and placebo groups.
• GSH levels remained stable in the APAP/NAC group but decreased significantly in the APAP/placebo group (P=0.033).
• Liver enzymes (ASAT, ALAT) were also monitored.

Conclusions:

• NAC does not influence the analgesic effectiveness of APAP.
• NAC administration can counteract the depletion of GSH induced by therapeutic APAP doses.
• These findings are significant for long-term APAP users and warrant further investigation in patient populations.